Thursday, April 10, 2014

Another reason to believe Mannkind shares are overvalued

I already believe Mannkind is overvalued due to it's $2.5 billion market cap, weak balance sheet, and lack of commercial partner.  Now they have another possible inhaled insulin competitor with a planned phase 3 trial next year.  Take a look at Adam's article for the details. 

Tuesday, April 8, 2014

Sunesis announces results at AACR - Wedbush reiterates $10 price target

As expected, Sunesis (SNSS) reported positive preliminary results of it's lead compound, Vosaroxin, in a phase 1b/2 study in AML and MDS.  The drug, combined with decitabine, had an overall response rate of 67% in the 24 patients treated.  Webush commented on the results and reiterated it's $10 price target on Sunesis. 

Monday, April 7, 2014

AACR Trading Opportunity - Sunesis

The American Association of Cancer Research 105th annual meeting is underway which sometimes provides opportunities for short term trades ahead of press releases for data presentations.  I think Sunesis (SNSS) is such an opportunity as updated phase 1b/2 data on it's lead compound, Vosaroxsin, in AML and MDS will be presented tomorrow.  I pulled the abstract and it's showing an 67% response rate which is a solid result and I'd expect a press release tomorrow to communicate these results.  I purchased 5,000 shares ahead of the data presentation.